Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Key Inclusion Criteria: * Age 18 years or above. * Diagnosis of chronic hand eczema defined as hand eczema, which has persisted for more than 3 months or returned twice or more within the last 12 months. * Disease severity graded as mild to severe according to IGA (i.e., IGA ≥2). * Recent history (within 1 year before the screening visit) of inadequate response to topical corticosteroid treatment or topical corticosteroid treatment being medically inadvisable. * Diagnostic patch testing performed within 3 years prior to the screening visit. Key Exclusion Criteria: * Concurrent skin diseases on the hands e.g tinnea manuum. * Active atopic dermatitis in regions other than the hands or psoriasis requiring medical treatment. * Clinically significant infection (e.g., impetiginised hand eczema) on the hands. * Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 4 weeks prior to baseline. * Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks prior to baseline. * Receipt of live attenuated vaccines 4 weeks prior to baseline. * Cutaneously applied treatment with immunomodulators (e.g., phosphodiesterase-4 (PDE-4) inhibitors, pimecrolimus, tacrolimus) or topical corticosteroids on the hands within 2 weeks prior to baseline. * Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to baseline. * Change in systemic antihistamine therapy within 2 week…